Legend Biotech (LEGN) Tops Q4 EPS by 9c

Legend Biotech (NASDAQ: LEGN) reported Q4 EPS of ($0.16), $0.09 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $186.52 million versus the consensus estimate of $173.99 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Voya Financial estimates Q2 alternative investment pre-tax loss of $9M-$19M
• Trump: U.S. strikes 'retribution for yesterday’s bombing of ships by Iran'